# Sanofi-Aventis U.S. LLC: Enoxaparin Sodium Injection to be discontinued

**Score:** 60/100

| Field | Value |
|---|---|
| Manufacturer | Sanofi-Aventis U.S. LLC |
| Drug | Enoxaparin Sodium Injection |
| Dosage form | Injection |
| Therapeutic category | Hematology |
| Status | To Be Discontinued |
| Stage | Manufacturer discontinuation |
| Presentations affected | 24 |
| Package NDCs | 0075-8020-10, 0075-8014-10, 0075-0624-30, 0075-0622-80, 0955-1006-10, 0955-1003-10, 0075-0626-03, 0075-8016-10, 0955-1008-10, 0075-8013-10, 0955-1016-01, 0955-1012-10, 0075-8018-10, 0075-2912-01, 0075-0621-60, 0075-8030-01, 0075-2915-01, 0955-1010-10, 0075-8022-10, 0075-0623-00 |
| Manufacturer supply note | Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation wit |
| Discontinued date | 2026-10-20 |
| First posted | 2026-10-20 |
| Updated | 2026-10-20 |

## Why this score
- The manufacturer is leaving the market.
- Sterile injectable: hospital and 503B demand.

Source: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list) (https://dps.fda.gov/drugshortages). Last refreshed: 2026-11-04T06:10:12.565Z.
From the openFDA drug shortages endpoint, which mirrors the FDA drug shortage list and can lag it by days. Availability and recovery notes are the manufacturer's own statements to FDA. Company and product level only. Verify with FDA and the manufacturer before acting.